Business Units

We direct our research efforts to two priority disease areas (Psychiatry & Neurology and Oncology) and other areas.

• Basic research (2–3 years): Discover and create new compounds that will be the starting point for medicines.
• Non-clinical studies (3–5 years): Examine the pharmacological activity and toxicity of candidate compounds for medicines using animals and cultured cells
• Make extensive use of cutting-edge technologies that have been developed by ourselves or obtained from academia or biotech companies.

Leveraging our global development organization, we aim to secure early regulatory approvals by forming strategic clinical development plans and conducting clinical developments efficiently.

• Clinical studies (3–7 years): Clinical studies for obtaining approval are divided into three phases and are conducted in clinical sites such as hospitals with the enrollment of healthy volunteers and patients after obtaining their informed consent.
• Design products and develop processes to make products that are easy to use.
• Submit new drug applications to the Ministry of Health, Labor and Welfare for approval.

We use strict quality controls to ensure the stable supply of our products.

• Consistently produce high quality products under our global supply chain system that covers procurement of raw materials through to distribution under strict quality controls.
• Provide medical institutions and dispensing pharmacies all over Japan with products.

We assure the quality of our products and product information at a global level throughout the lifecycle of our products, from the development stage through to post-marketing stage.

• Established a quality assurance and audit system that delivers global “A-N-SHI-N* .”
• Conduct integrated management of safety information, including adverse reactions, from the development stage (clinical studies) to the postmarketing stage and engage in proactive safety measures and provision of information.

• * A-N-SHI-N: Trustworthiness, reliability, peace of mind, making people feel reassured and safe.

We create, provide, and disseminate information of high standard that is based on robust scientific evidence and meets medical needs.

• Build up and disseminate evidence to satisfy unmet medical needs.

We provide healthcare professionals with information on the proper use of our pharmaceutical products, by building an information system which caters to changes in the market environment.

• Through an information provision system capable of adapting to market changes, provide healthcare professionals with information on proper use of products.

In the interest of expanding our development pipeline, we are proactively pursuing opportunities for M&A, in-licensing, and alliance making, while also promoting alliances with external research institutions.

• Actively promote strategic investment in acquisitions and in-licensing
• Consider a broad range of assets and alliances in our focus areas for in-licensing, with a priority on late-stage development assets and approved products.
• Enter into research alliances with research institutions that include universities in Japan and overseas, as well as biotech companies with innovative technologies.

We play our part in tackling social issues by listening to the requests and wishes of our stakeholders, and reflecting them in our business operations as well as CSR activities.

We recognize the responsibility we bear for our own environmental impact, and we are working to reduce our environmental impact across all business activities.